Recent Updates
Recently added Catalysts

iFS Femtosecond Laser System

Phase 2

Corneal Astigmatism | Unknown | Ophthalmology |Abbott Laboratories|Last Updated: Jun 4, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment40

FDA Designations

No designations recorded

Clinical trial landscape

iFS Femtosecond Laser System · 1 trial · 1 indication

Phase 2 1
NCT01348854Safety and Effectiveness of Arcuate Incisions Performed With the iFS Femtosecond Laser SystemCorneal Astigmatism
COMPLETED40 Analytics
PHASE2COMPLETED
Safety and Effectiveness of Arcuate Incisions Performed With the iFS Femtosecond Laser System
Corneal AstigmatismUnlock trial analytics

Study Endpoints

Primary Endpoints

Reduction of Astigmatism
6 months

Reduction of astigmatism as determined by manifest refractive cylinder

Secondary Endpoints

Percent of Eyes With Loss of ≥ 2 Lines of Best Spectacle Corrected Visual Acuity (BSCVA)
6 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Natural AstigmatismEXPERIMENTALUse of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.
Post Cataract with Residual AstigmatismEXPERIMENTALUse of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.

Interventions

NameTypeDescription
iFS Femtosecond Laser SystemDEVICEarcuate incisions placed with the iFS femtosecond laser
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites4

Inclusion Criteria: 1. Male or female, of any race, and at least 21 years of age at the time of pre-op exam 2. Corneal astigmatism, as determined by topographic keratometry, of 0.75 D to 4.00 diopters (D) 3. Best Spectacle Corrected Distance Visual Acuity (BSCVA) 1. Group 1: * Natural as...

Countries:AustriaFranceGermany
Unlock Eligibility Criteria

Frequently asked questions about iFS Femtosecond Laser System

What is the iFS Femtosecond Laser System used for?

The iFS Femtosecond Laser System is used for corneal astigmatism, a condition in which the cornea is irregularly shaped. It is an ophthalmology device being developed by Abbott Laboratories. The system is designed to perform arcuate incisions to address corneal astigmatism.

Who makes the iFS Femtosecond Laser System?

Abbott Laboratories (ticker: ABT) is the developer of the iFS Femtosecond Laser System. The company is conducting clinical research on the device for the treatment of corneal astigmatism in the field of ophthalmology.

What phase is the iFS Femtosecond Laser System in?

The iFS Femtosecond Laser System is in Phase 2 clinical development. It is an investigational device, not yet approved, and is being studied for its safety and effectiveness in treating corneal astigmatism. One Phase 2 trial has been completed.

What clinical trials is the iFS Femtosecond Laser System in?

The iFS Femtosecond Laser System has one completed clinical trial, NCT01348854, titled "Safety and Effectiveness of Arcuate Incisions Performed With the iFS Femtosecond Laser System." This Phase 2 study enrolled 40 participants with corneal astigmatism in Austria, France, and Germany.

Is the iFS Femtosecond Laser System the same as a laser used for LASIK?

The iFS Femtosecond Laser System is a femtosecond laser used to create arcuate incisions in the cornea to treat corneal astigmatism. It is not described as a LASIK laser. The device is being studied specifically for corneal astigmatism correction.